Search

Displaying results 3541 - 3550 of 8700 in total
  1. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety. … ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).

  2. Drug

    PF-04856884

    go.drugbank.com/drugs/DB17550
    Investigational

    PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. … [A257291] It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).

  3. Drug

    Ebastine

    go.drugbank.com/drugs/DB11742
    ApprovedInvestigationalWithdrawn

    Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.

    Categories: Antihistamines for Systemic Use, Cytochrome P-450 Substrates
  4. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).

  5. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor], a CFTR potentiator, for

  6. Drug

    Mefenamic acid

    go.drugbank.com/drugs/DB00784
    Approved

    It is an inhibitor of cyclooxygenase.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  7. Drug

    Polycarbophil

    go.drugbank.com/drugs/DB09311
    ApprovedWithdrawn

    This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. … Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.

  8. Drug

    Rebamipide

    go.drugbank.com/drugs/DB11656
    ApprovedInvestigational

    Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  9. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was...

    Categories: Antipsoriatics for Topical Use, Corticosteroid Hormone Receptor Agonists
  10. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

    Categories: Agents for Dermatitis, Excluding Corticosteroids